High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids

Endocrine-Related Cancer

Volumn 16, Issue 3, 2009, Pages 953-966

  Andersson, Ellinor ^a   Swärd, Christina ^a   Stenman, Göran ^a   Ahlman, Håkan ^a   Nilsson, Ola ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARCINOID; CHROMOSOME 14; CHROMOSOME 18; CHROMOSOME GAIN; CHROMOSOME LOSS; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE NUMBER; GENETIC GAIN; HUMAN; HUMAN TISSUE; ILEUM CARCINOID; MALE; OVERALL SURVIVAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOID TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 14; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; ILEAL NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS;

EID: 72749102699     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0052     Document Type: Article

References (49)

1. Auer RL, Starczynski J, McElwaine S, Bertoni F, Newland AC, Fegan CD & Cotter FE 2005 Identification of a potential role for POU2AF1 and BTG4 in the deletion of 11q23 in chronic lymphocytic leukemia. Genes, Chromosomes and Cancer 43 1-10. (Pubitemid 40490350)
2. Van Buren G II, Rashid A, Yang AD, Abdalla EK, Gray MJ, Liu W, Somcio R, Fan F, Camp ER, Yao JC et al. 2007 The development and characterization of a human midgut carcinoid cell line. Clinical Cancer Research 13 4704-4712. (Pubitemid 47294776)
3. Capella C, Solcia E, Sobin LH & Arnold R 2000 Endocrine tumours of the small intestine. In Pathology and Genetics, Tumours of the digestive system, Eds SR Hamilton & LA Aaltonen. Lyon, France: IARC Press.
4. Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR & Rashid A 2003 CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 22 924-934. (Pubitemid 36255828)
5. Choi IS, Estecio MR, Nagano Y, Kim do H, White JA, Yao JC, Issa JP & Rashid A 2007 Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Modern Pathology 20 802-810.
6. Danen-van Oorschot AA, Voskamp P, Seelen MC, van Miltenburg MH, Bolk MW, Tait SW, Boesen-de Cock JG, Rohn JL, Borst J & Noteborn MH 2004 Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing. Cell Death and Differentiation 11 564-573. (Pubitemid 38660141)
7. Faiss S, Pape UF, Böhmig M, Dö rffel Y, Mansmann U, Golder W, Riecken EO & Wiedenmann B 2003 Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology 21 2689-2696.
8. Hoeflich KP & Ikura M 2004 Radixin: cytoskeletal adopter and signaling protein. International Journal of Biochemistry and Cell Biology 36 2131-2136. (Pubitemid 39094436)
9. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW & Lee C 2004 Detection of large-scale variation in the human genome. Nature Genetics 36 949-951. (Pubitemid 39167488)
10. Jakobsen AM, Andersson P, Saglik G, Andersson E, Kölby L, Erickson JD, Forssell-Aronsson E, Wängberg B, Ahlman H & Nilsson O 2001 Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours. Journal of Pathology 195 463-472. (Pubitemid 33069672)
11. Kim do H, Nagano Y, Choi IS, White JA, Yao JC & Rashid A 2008 Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes, Chromosomes and Cancer 47 84-92.
12. Kölby L, Persson G, Franzen S & Ahren B 2003 Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. British Journal of Surgery 90 687-693. (Pubitemid 36760596)
13. Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN & Shivdasani RA 2008 High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes, Chromosomes and Cancer 47 591-603. (Pubitemid 351748345)
14. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J & Hahn RG 1986 Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. New England Journal of Medicine 315 663-666. (Pubitemid 16055931)
15. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'Dorisio TM, Valkema R, Bodei L, Chinol M et al. 2005 Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. Journal of Nuclear Medicine 46 62S-66S. (Pubitemid 47619020)
16. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO & Krenning EP 2008 Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology 26 2124-2130.
17. Kytölä S, Höög A, Nord B, Cedermark B, Frisk T, Larsson C & Kjellman M 2001 Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. American Journal of Pathology 158 1803-1808. (Pubitemid 32422945)
18. Liu L, Broaddus RR, Yao JC, Xie S, White JA, Wu TT, Hamilton SR & Rashid A 2005 Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Modern Pathology 18 1632-1640. (Pubitemid 41670664)
19. Löllgen RM, Hessman O, Szabo E, Westin G & Åkerström G 2001 Chromosome 18 deletions are common events in classical midgut carcinoid tumors. International Journal of Cancer 92 812-815. (Pubitemid 32467369)
20. Modlin IM, Lye KD & Kidd M 2003 A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 934-959. (Pubitemid 36173145)
21. Novak RL & Phillips AC 2008 Adenoviral-mediated Rybp expression promotes tumor cell-specific apoptosis. Cancer Gene Therapy 15 713-722.
22. Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, Yeatman TJ, Carey L, Duhaine L & Kvols LK 2006 Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Annals of Surgical Oncology 13 572-581.
23. Pfragner R, Wirnsberger G, Niederle B, Behmel A, Rinner I, Mandl A, Wawrina F, Luo JS, Adamiker D, Hoger H et al. 1996 Establishment of a continuous cell line from a human carcinoid of the small intestine (KRJ-I): characterization and effects of 5-azacytidine on proliferation. International Journal of Oncology 8 513-520. (Pubitemid 26082169)
24. Rakha EA, Green AR, Powe DG, Roylance R & Ellis IO 2006 Chromosome 16 tumor-suppressor genes in breast cancer. Genes, Chromosomes and Cancer 45 527-535. (Pubitemid 43727159)
25. Rindi G, Klöppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A et al. 2007 TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 451 757-762. (Pubitemid 47497934)
26. Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, Lasser P, Schlumberger M & Ducreux M 2003 Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. European Radiology 13 136-140. (Pubitemid 36790502)
27. Sablina AA, Chen W, Arroyo JD, Corral L, Hector M, Bulmer SE, DeCaprio JA & Hahn WC 2007 The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell 129 969-982. (Pubitemid 46813152)
28. Sarmiento JM &Que FG 2003 Hepatic surgery for metastases from neuroendocrine tumors. Surgical Oncology Clinics of North America 12 231-242. (Pubitemid 36210867)
29. Schmalhofer O, Brabletz S & Brabletz T 2009 E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer and Metastasis Reviews 28 151-166.
30. Shields JM, Rogers-Graham K & Der CJ 2002 Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. Journal of Biological Chemistry 277 9790-9799.
31. Sjögren H, Nilsson O, Behrendt M, Kölby L, Jacobsen Levin AM, Ahlman H & Stenman G 2000 Multicolor spectral karyotype analysis of a transplantable human ileal carcinoid. International Journal of Molecular Medicine 6 629-633.
32. Stancu M, Wu TT, Wallace C, Houlihan PS, Hamilton SR & Rashid A 2003 Genetic alterations in goblet cell carcinoids of the vermiform appendix and comparison with gastrointestinal carcinoid tumors. Modern Pathology 16 1189-1198. (Pubitemid 38018599)
33. Stridsberg M, Öberg K, Li Q, Engström U & Lundqvist G 1995 Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. Journal of Endocrinology 144 49-59.
34. Sun X, Gong Y, Talamonti MS & Rao MS 2002 Expression of cell adhesion molecules, CD44s and E-cadherin, and microvessel density in carcinoid tumors. Modern Pathology 15 1333-1338. (Pubitemid 35463002)
35. Terris B, Meddeb M, Marchio A, Danglot G, Flejou JF, Belghiti J, Ruszniewski P & Bernheim A 1998 Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system. Genes, Chromosomes and Cancer 22 50-56. (Pubitemid 28217806)
36. Tokunou M, Niki T, Saitoh Y, Imamura H, Sakamoto M & Hirohashi S 2000 Altered expression of the ERM proteins in lung adenocarcinoma. Laboratory Investigation 80 1643-1650. (Pubitemid 30844048)
37. Tönnies H, Toliat MR, Ramel C, Pape UF, Neitzel H, Berger W & Wiedenmann B 2001 Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut 48 536-541. (Pubitemid 32234799)
38. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y & Tokino T 2008 Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Research 68 4123-4132.
39. Walch AK, Zitzelsberger HF, Aubele MM, Mattis AE, Bauchinger M, Candidus S, Prauer HW, Werner M & Höfler H 1998 Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. American Journal of Pathology 153 1089-1098. (Pubitemid 28465832)
40. Wang SS, Esplin ED, Li JL, Huang L, Gazdar A, Minna J & Evans GA 1998 Alterations of the PPP2R1B gene in human lung and colon cancer. Science 282 284-287. (Pubitemid 28487198)
41. Wang GG, Yao JC, Worah S, White JA, Luna R, Wu TT, Hamilton SR & Rashid A 2005 Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors. Modern Pathology 18 1079-1087. (Pubitemid 41224498)
42. Wängberg B, Westberg G, Tylen U, Tisell L, Jansson S, Nilsson O, Johansson V, Schersten T & Ahlman H 1996 Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World Journal of Surgery 20 892-899. (Pubitemid 26281920)
43. Weckström P, Hedrum A, Makridis C, Akerström G, Rastad J, Scheibenpflug L, Uhlén M, Juhlin C & Wilander E 1996 Midgut carcinoids and solid carcinomas of the intestine: differences in endocrine markers and p53 mutations. Endocrine Pathology 7 273-279. (Pubitemid 126715758)
44. Westberg G, Wängberg B, Ahlman H, Bergh CH, Beckman- Suurküla M & Caidahl K 2001 Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. British Journal of Surgery 88 865-872. (Pubitemid 32823842)
45. Yang Z, Chang YJ, Miyamoto H, Ni J, Niu Y, Chen Z, Chen YL, Yao JL, di Sant'Agnese PA & Chang C 2007 Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Molecular Endocrinology 21 343-358. (Pubitemid 46184889)
46. Younes N, Fulton N, Tanaka R, Wayne J, Straus FH II & Kaplan EL 1997 The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Cancer 79 1804-1808. (Pubitemid 27176364)
47. Zhang HY, Rumilla KM, Jin L, Nakamura N, Stilling GA, Ruebel KH, Hobday TJ, Erlichman C, Erickson LA & Lloyd RV 2006 Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors. Endocrine 30 299-306. (Pubitemid 47010966)
48. Zhao J, de Krijger RR, Meier D, Speel EJ, Saremaslani P, Muletta-Feurer S, Matter C, Roth J, Heitz PU & Komminoth P 2000 Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis. American Journal of Pathology 157 1431-1438. (Pubitemid 30943200)
49. Zhao J, Moch H, Scheidweiler AF, Baer A, Schaffer AA, Speel EJ, Roth J, Heitz PU & Komminoth P 2001 Genomic imbalances in the progression of endocrine pancreatic tumors. Genes, Chromosomes and Cancer 32 364-372. (Pubitemid 33055121)